RS56255430 Unknown gene
Upload your DNA to see your genotype for this variant.
GWAS Studies (20)
| Trait | Risk Allele | OR / Beta | P-value | Study |
|---|---|---|---|---|
| Type 2 diabetes (PheCode 250.2) | A | β: 0.078 | 8E-26 | PubMed |
| Diabetes mellitus (PheCode 250) | A | β: 0.078 | 2E-25 | PubMed |
| Hemoglobin A1c (HbA1c, maximum, inv-norm transformed) | A | β: 0.052 | 8E-24 | PubMed |
| LDL x depression interaction (2df test) | A | OR: 1.25 | 2E-23 | PubMed |
| Diabetes / "Sugar" | A | β: 0.098 | 5E-23 | PubMed |
| LDL x depression interaction (2df test) | A | OR: 1.57 | 6E-23 | PubMed |
| Hemoglobin A1c (HbA1c, mean, inv-norm transformed) | A | β: 0.052 | 8E-23 | PubMed |
| Malignant neoplasm of liver, primary (PheCode 155.1) | A | OR: 0.37 | 3E-20 | PubMed |
| Estimated glomerular filtration rate (creatinine) | C | OR: 9.2 | 4E-20 | PubMed |
| Malignant neoplasm of liver, primary (PheCode 155.1) | A | OR: 0.4 | 4E-19 | PubMed |
| Creatinine levels (UKB data field 30700) | C | β: 0.025 | 2E-18 | PubMed |
| LDL x anxiety interaction (2df test) | A | OR: 0.22 | 2E-18 | PubMed |
| Cancer of liver and intrahepatic bile duct (PheCode 155) | A | OR: 0.33 | 7E-18 | PubMed |
| LDL x anxiety interaction (2df test) | A | OR: 0.7 | 2E-17 | PubMed |
| Estimated glomerular filtration rate based on creatinine and cystatin C in bottom 99% of individuals by creatinine levels | — | OR: 3.64 | 1E-16 | PubMed |
| Cancer of liver and intrahepatic bile duct (PheCode 155) | A | OR: 0.34 | 2E-16 | PubMed |
| Hemoglobin A1c (HbA1c, minimum, inv-norm transformed) | A | β: 0.042 | 3E-15 | PubMed |
| Cholesterol to Total Lipids in Medium LDL percentage | C | β: 0.03 | 6E-15 | PubMed |
| Creatinine levels in bottom 99% of individuals by creatinine levels | — | OR: 0.33 | 2E-14 | PubMed |
| Serum levels of protein PCYOX1 | C | OR: 0.24 | 3E-14 | PubMed |